<DOC>
	<DOCNO>NCT00552240</DOCNO>
	<brief_summary>The aim clinical trial compare efficacy safety ritonavir ( RTV ) -boosted atazanavir nevirapine , background emtricitabine tenofovir disoproxil fumarate ( DF ) .</brief_summary>
	<brief_title>Nevirapine vs. Atazanavir Boosted With Ritonavir Background Truvada Human Immunodeficiency Virus ( HIV ) Infected Naive Patients ( NEwArT )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Inclusion criterion : 1 . Signed informed consent accordance Good Clinical Practice ( GCP ) local regulatory requirement prior trial participation 2 . HIV1 infect male female great equal 18 year age document positive serology Enzymelinked Immuno Sorbert Assay ( ELISA ) confirm Western blot 3 . No prior nucleoside reverse transcriptase inhibitor ( NRTI ) nonnucleoside reverse transcriptase inhibitor ( NNRTI ) use 10 day AND 4 . No prior use class antiretrovirals ( ARVs ) 2 week duration 5 . Males CD4+ count le 400 cells/mm cub female CD4+ count le 250 cells/mm cub 6 . NVP ATV/r susceptibility screen HIV1 genotypic resistance assay 7 . Adequate renal function define calculated creatinine clearance great equal to50 ml/min accord CockcroftGault formula 8 . Karnofsky score great equal 70 ( see Appendix 10.7 ) 9 . Acceptable medical history , assess investigator Exclusion criterion : 1 . History active drug alcohol abuse within 2 year prior study entry ( investigator discretion ) 2 . Hepatic cirrhosis stage ChildPugh B C hepatic impairment 3 . Female patient childbearing potential : positive serum pregnancy test screening , breast feeding , plan become pregnant , willing use barrier method contraception , willing use method contraception ethinyl estradiol contain oral contraceptive 4 . Laboratory parameter great Division Aids ( National Institute Health , USA ) ( DAIDS ) grade 2 ( triglyceride great DAIDS grade 3 , total cholesterol restriction , see Appendix 10.1 ) 5 . Active hepatitis B C disease , define HBsAgpositive Hepatitis C Virus ( HCV ) RNA positive alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ALT/AST great than2.5x Upper Limit Normal ( ULN ) ( great DAIDS grade 1 ) 6 . Known hypersensitivity ingredient nevirapine atazanavir 7 . Patients receive concomitant treatment permit , list Appendix 10.6 8 . Use investigational medication within 30 day study entry trial 9 . Use immunomodulatory drug within 30 day study entry trial ( e.g. , interferon , cyclosporin , hydroxyurea , interleukin 2 , chronic treatment prednisone ) 10 . Patients Progressive Multifocal Leukoencephalopathy ( PML ) , visceral Kaposi 's Sarcoma ( KS ) , and/or lymphoma 11 . Any AIDS defining illness unresolved , symptomatic stable treatment least 12 week screen visit 12 . Patients receive systemic chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>